Literature DB >> 16773267

Necrotising cutaneous lesions as a side effect of glatiramer acetate.

Isabel Bosca, Maria Bosca, Antonio Belenguer, Monserrat Evole, Miguel Hernandez, Bonaventura Casanova, Francisco Coret.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16773267     DOI： 10.1007/s00415-006-0233-9

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  10 in total

1.  Severe necrotising cutaneous lesions complicating treatment with interferon beta-1a.

Authors:  A J Radziwill; S Courvoisier
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-07       Impact factor: 10.154

2.  Localized lipoatrophy after prolonged treatment with copolymer 1.

Authors:  G L Mancardi; A Murialdo; F Drago; C Brusati; R Croce; M Inglese; S Ratto
Journal:  J Neurol       Date:  2000-03       Impact factor: 4.849

3.  Severe necrotizing cutaneous lesions complicating treatment with interferon beta-1b.

Authors:  W A Sheremata; J R Taylor; G W Elgart
Journal:  N Engl J Med       Date:  1995-06-08       Impact factor: 91.245

4.  Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.

Authors:  K P Johnson; B R Brooks; C C Ford; A Goodman; J Guarnaccia; R P Lisak; L W Myers; H S Panitch; A Pruitt; J W Rose; N Kachuck; J S Wolinsky
Journal:  Mult Scler       Date:  2000-08       Impact factor: 6.312

5.  Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis.

Authors:  Noemi Soós; Kaweh Shakery; Ulrich Mrowietz
Journal:  Am J Clin Dermatol       Date:  2004       Impact factor: 7.403

6.  Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.

Authors:  K P Johnson; B R Brooks; J A Cohen; C C Ford; J Goldstein; R P Lisak; L W Myers; H S Panitch; J W Rose; R B Schiffer; T Vollmer; L P Weiner; J S Wolinsky
Journal:  Neurology       Date:  1998-03       Impact factor: 9.910

7.  Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.

Authors:  K P Johnson; B R Brooks; J A Cohen; C C Ford; J Goldstein; R P Lisak; L W Myers; H S Panitch; J W Rose; R B Schiffer
Journal:  Neurology       Date:  1995-07       Impact factor: 9.910

8.  [Livedo-like dermatitis (Nicolau's syndrome) after injection of Copolymer-1 (Glatiramer acetate)].

Authors:  C Gaudez; S Regnier; S Aractingi; O Heinzlef
Journal:  Rev Neurol (Paris)       Date:  2003-05       Impact factor: 2.607

9.  [Animal experiment studies of embolia cutis medicamentosa].

Authors:  K H Albrecht; K Littmann; H J Richter; F W Eigler
Journal:  Langenbecks Arch Chir       Date:  1984

10.  Lipoatrophy in patients with multiple sclerosis on glatiramer acetate.

Authors:  Catherine M Edgar; Donald G Brunet; Paul Fenton; E Vee McBride; Peter Green
Journal:  Can J Neurol Sci       Date:  2004-02       Impact factor: 2.104
  10 in total
  3 in total

Review 1.  Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 2.

Authors:  Aryan Rafiee Zadeh; Keyvan Ghadimi; Akram Ataei; Mozhde Askari; Neda Sheikhinia; Nooshin Tavoosi; Masih Falahatian
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2019-08-15

Review 2.  Cutaneous Adverse Effects of Neurologic Medications.

Authors:  Eman Bahrani; Chloe E Nunneley; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 6.497

3.  Glatiramer acetate (copaxone) modulates platelet activation and inhibits thrombin-induced calcium influx: possible role of copaxone in targeting platelets during autoimmune neuroinflammation.

Authors:  Sarah C Starossom; Tatyana Veremeyko; Marina Dukhinova; Amanda W Y Yung; Eugene D Ponomarev
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.